All In Biotech

Drug Trial Radar · NCT02792465

A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors

An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-402257 Administered Orally to Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Planned (sponsor's estimate)

Start

Nov 11, 2016

Primary completion

Jun 12, 2025

Study completion Jun 12, 2025

Sponsor

Lead sponsor
University Health Network, TorontoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 7, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1 study of investigational agent CFI-402257 in patients with advanced cancer. The purpose of this study is to see how safe and tolerable CFI-402257 is in cancer patients as well as the pharmacokinetics (PK). This study is the first time that CFI-402257 is given to humans.

Conditions

  • Advanced Solid Cancers
  • Breast Cancer

Interventions

  • CFI-402257Drug

  • FulvestrantDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Highest dose level that does not lead to unacceptable toxicity in two or more patients in a dosing cohortTime frame: 2 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • BC Cancer Agency

    Vancouver, British Columbia, Canada

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.